

## **OBESITY**

Prof. Assim A Alfadda MD, FRCPC, FACP, MSc

المركز الجامعي لأبحاث السمنة كلية الطب – جامعة الملك سعود www.obesitycenter.edu.sa







#### Objectives

- \* Why to study obesity?
- \* What is obesity?
- \* Body weight regulation?
- \* Why do people come obese?
- \* How to manage obesity?


#### **Obesity and mortality**




#### Obesity: cardiovascular risk



#### Physical Effects of Obesity



# Nonalcoholic fatty liver disease



Steatohepatitis

**Fibrosis** 

NEJM 2002;346:1221-1230

### Obesity

- WHO:
  - "Abnormal or excessive fat accumulation in adipose tissue, to the extent that health is impaired"(1,2)
- Presence of an abnormal absolute amount or relative proportion of body fat.

- 1. WHO. Obesity: Preventing and Managing the Global Epidemic. Technical report 894. Geneva: WHO, 2000;256
- Garrow JS. Obesity and Related Diseases. Edinburgh: Churchill Livingstone, 1998.

## Amount of adipose tissue in human body

- Possible
- Difficult
- Time consuming
- Expensive

ve vise in the field mappropriate to use in the

#### Surrogate measures of adiposity

- Ideal body weight
- Weight
- Anthropometric measures
- Body mass index (BMI):
- Recommended by WHO
- Relatively reliable except in:
  - Extremes of age or height
  - Very fit individuals with muscular build

## WHO recommended definition of obesity (2000)

Classification	BMI(kg/m <sup>2</sup> )	Risk of co- morbidities
Underweight	<18.5	LOW (but risk of other clinical problems increased)
Normal range	18.5-24.9	Average
Overweight	>25.0	
Pre-obese	25-29.9	Mildly increase

## WHO recommended definition of obesity (2000)

Classification	BMI(kg/m <sup>2</sup> )	Risk of co- morbidities
Obese	>30	
Class I	30-34.9	Moderate
Class II	35-39.9	Severe
Class III	>40.0	Very severe

WHO. Obesity: Preventing and Managing the Global Epidemic. Technical report 894. Geneva: WHO, 2000

#### Definition

Production of ethnic-specific cut-points for obesity

BMI

Body fatness

Morbidity & Mortality

Additional interim cut-point of BMI of 23kg/m<sup>2</sup> or greater to indicate **overweight** 

in Asian populations and a BMI of 25kg/m<sup>2</sup> to represent a higher level of risk equivalent to **obesity** 


WHO (Western Pacific Region), International Obesity Taskforce and International Association for the Study of Obesity. The Asia-Pacific Perspective: Redefining obesity and its Treatment. Sydney: Health Communication, 2000

### **Central Obesity**

- Central or visceral obesity is associated with more metabolic disease:
- DM<sub>2</sub>
- Hypertension
- Dyslipidemia
- ? How to assess central or visceral obesity?

#### Waist Measurement or BMI?





#### **Central Obesity**

- MRI
- Dual X-ray absorptiometry (DEXA)
- Single CT slice L4/L5
- Waist: hip ratio
- Waist circumference

The narrowest circumference midway between the lower border of the ribs and the upper border of the iliac crest, taken from the side

#### Waist circumference (measure of visceral obesity)

Population	Risk of metabolic complications of obesity		
	Increased	Substantially Increased	
Caucasian (WHO)			
Men	>94 cm	>102 cm	
Women	>80 cm	>88 cm	
Asia (IASO/IOTF/WHO)			
Men		>90 cm	
Women		>80 cm	
China (wgoc)			
Men		>85 cm	
Women		>80 cm	

#### Obesity in children

- Growth charts
- BMI-for-age reference charts
- "International standard" BMI-for-age:
- Cole et al. (BMJ 2000; 320:1240-1243)
- Combined sample of seven countries
- By tracking the percentile representing a BMI of 25kg/m<sup>2</sup> and 30kg/m<sup>2</sup> at 18 years backthrough to birth.
- It's use will provide a standard definition and enable meaningful comparisons to be made between countries.

#### Cole et al. (BMJ 2000; 320:1240-1243)





Fig 6 International cut off points for body mass index by sex for overweight and obesity, passing through body mass index 25 and 30 kg/m<sup>2</sup> at age 18 (data from Brazil, Britain, Hong Kong, Netherlands, Singapore, and United States)

#### Cole et al. (BMJ 2000; 320:1240-1243)


	Body mass index 25 kg/m²		Body mass index 30 kg/m²	
Age (years)	Males	Females	Males	Females
2	18.41	18.02	20.09	19.81
2.5	18.13	17.76	19.80	19.55
3	17.89	17.56	19.57	19.36
3.5	17.69	17.40	19.39	19.23
4	17.55	17.28	19.29	19.15
4.5	17.47	17.19	19.26	19.12
5	17.42	17.15	19.30	19.17
5.5	17.45	17.20	19.47	19.34
6	17.55	17.34	19.78	19.65
6.5	17.71	17.53	20.23	20.08
7	17.92	17.75	20.63	20.51
7.5	18.16	18.03	21.09	21.01
8	18.44	18.35	21.60	21.57
8.5	18.76	18.69	22.17	22.18
9	19.10	19.07	22.77	22.81
9.5	19.46	19.45	23.39	23.46
10	19.84	19.86	24.00	24.11
10.5	20.20	20.29	24.57	24.77
11	20.55	20.74	25.10	25.42
11.5	20.89	21.20	25.58	26.05
12	21.22	21.68	26.02	26.67
12.5	21.56	22.14	26.43	27.24
13	21.91	22.58	26.84	27.76
13.5	22.27	22.98	27.25	28.20
14	22.62	23.34	27.63	28.57
14.5	22.96	23.66	27.98	28.87
15	23.29	23.94	28.30	29.11
15.5	23.60	24.17	28.60	29.29
16	23.90	24.37	28.88	29.43
16.5	24.19	24.54	29.14	29.56
17	24.46	24.70	29.41	29.69
17.5	24.73	24.85	29.70	29.84
18	25	25	30	30

### **Etiology & Pathogenesis**

- Multifactorial
- Biochemical/Dietary/behavioral pathways.
- Imbalance between energy intake and energy expenditure



#### Body weight and composition regulation



## Hypothalamic modulators of food intake

Orexigenic	Anorexigenic
NPY	CART
AGRP	CCK
MCH	CRH
Galanin	α-MSH
Orexin	Insulin
Ghrelin	GLP-1
Noradrenaline	PYY 3-36
Endocannabinoids	Leptin
μ, κ Opioids	Urocortin
Neurotransmitters	Bombesin

### **Etiology & Pathogenesis**

Body weight is ultimately determined by the interaction of:

- Genetic
- Environmental and
- Psychosocial factors
- Acting through several physiological mediators of food intake and energy expenditure

■(Jebb, 1997; Cooling *et al.* 1998; Weinsier *et al.* 1998).

#### Etiological classification of obesity

- Neuroendocrine disease
- Drug-induced
- Dietary
- Reduced energy expenditure
- Genetic factors

### Neuroendocrine obesity

- Ventromedial hypothalamus damage:
- Tumors
- Inflammatory lesions
- Other hypothalamic disease
- Cushing disease


### Drug-induced obesity

- Hyperinsulinism
- Insulin
- Sulfonylureas
- Antidepressants
- Antiepileptics
- Neuroleptics


### Dietary obesity

- High carbohydrate diet
- Hi fat diet


#### Change in BMI (kg/m²) from 1989 to 1991



#### Change in BMI (kg/m²) from 1989 to 1991



## Change in BMI (kg/m²) from 1989 to 1991



### Energy expenditure

- Resting metabolism:
- 800 to 900 kcal/m<sup>2</sup>/24hr
- Females < Males
- Declines with age
- Physical exercise:
- ~ 1/3 of daily energy expenditure
- Most easily manipulated

#### Energy expenditure

- Dietary thermogenesis (thermic effect of food):
- Energy expenditure which follow the ingestion of meal
- May dissipate ~ 10% of the ingested calories
- In the obese, the thermic effects of food are reduced (especially in patients with diabetes)
- Adaptive thermogenesis:
- With acute over or underfeeding
- Shift in overall metabolism as large as 20%

- Dysmorphic or syndromic obesity:
- Bardet-Biel syndrome
- Alström syndrome
- Carpenter syndrome
- Cohen syndrome
- Prader-Willi syndrome

- Single-gene cause of obesity:
- Leptin and leptin gene deficiency
- POMC deficiency
- Genetic defects with nonsyndromic obesity:
- Melanocortin receptor system abnormalities

- Genetic susceptibility to obesity:
- If both parents are obese ~ 80% of the offspring will be obese
- If only one parent ~ 10% of the offspring will be obese
- Studies with identical twins:
- Hereditary factors account ~ 70%
- Environmental (diet, physical inactivity, or both) account ~ 30% of the variation in the body weight

- The notion that obesity is a genetic disorder is misleading:
- The prevalence of obesity has increased markedly, world-wide, in recent years, yet genes have not changed.
- Changes occur within population when migration occurs.

Phenotypic expression of genes for obesity are environment specific Obesity is a disorder of gene-environment interaction

# METABOLIC CONSEQUENCES OF DELETING THE MITOCHONDRIAL GLYCEROL 3-PHOSPHATE DEHYDROGENASE GENE IN MICE

Am J Physiol Regul Integr Comp Physiol 287: R147-R156, 2004.
First published March 18, 2004; 10.1152/ajpregu.00103.2004.


Mice with deletion of the mitochondrial glycerol-3-phosphate dehydrogenase gene exhibit a thrifty phenotype: effect of gender


Assim Alfadda, Rosangela A. DosSantos, Zaruhi Stepanyan, Husnia Marrif, and J. Enrique Silva

Division of Endocrinology, Lady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2

Submitted 13 February 2004; accepted in final form 4 March 2004

#### The NADH glycerol 3-phosphate shuttle






#### **Objectives**


## We studied the consequences of deleting the mGPD gene regarding:


- Responses to fat- or carbohydrate-rich diets.
- Tolerance and responses to caloric restriction and fasting.


#### Serum Triglycerides




#### **Food intake**












#### **Body Weight**




#### Weight Loss



## Change in Energy Expenditure



## Core temperature change at 22°C



#### Conclusions


Thus,

The mGPD can be considered a spendthrift enzyme that significantly contributes to obligatory thermogenesis

#### Conclusions

 The mGPD gene may play a role in the development of obesity if we consider the readiness with which some patients gain weight, and the difficulties the have to lose weight when undergoing a low calorie diets

#### Conclusions



Factors participating in body-weight maintenance



#### **Obesity**

### Management

#### **Diet**

Careful Training in:
 Selection of lower fat, lower carb foods
 Modified food guide pyramid
 Increase fruits & vegetables
 Lower fat preparation techniques
 Estimation of portion size

#### **Atkins diet 6 mo results**





Figure 1. Mean (±SE) Decrease in Weight between Subjects on the Low-Carbohydrate Diet and Those on the Low-Fat Diet.

BMI 42.9, 40% diabetic. TG, insulin, glucose; p<0.01.

#### **Atkins diet 24 months**




33 each group; 1/3 dropouts; no diabetics, BMI 33; ↓ TG ↑ HDL

#### Dangers of Atkins diet

- High saturated fat and cholesterol: CVD
- High protein: decline in renal function, urinary calcium losses (osteoporosis)
- Lack of fiber: increase colon cancer risk
- Avoidance of carbs results in decreased intakes of essential vitamins (thiamin, folate,B6) and anti-oxidant phytochemicals


#### Exercise for Weight Maintenance



#### **Orlistat**

- A lipase inhibitor, reduces the absorption of dietary fat
- Lowers Cholesterol (4-11%) & LDL (5-10%)
- Major C/I:
- Chronic malabsorption syndrome
- Cholestasis
- Pregnancy and breast feeding
- Dose:
- 120 mg/ immediately before, during, or up to 1 hour after each main meal (up to max. 360mg/day)
- Max. period of treatment is 2 year

## Body Weight Over 2 Years of treatment with orlistat



What interventions should we add to weight reducing diets in adults with obesity? A systematic review of randomized controlled trials of adding drug therapy, exercise, behaviour therapy or combinations of these interventions

12 months: Drug therapy: Adding orlistat to diet Adding sibutramine to diet + Exercise: Adding exercise to diet Adding exercise to diet and BT Behaviour therapy (BT): Adding BT to diet Adding BT to sibutramine and diet Combined interventions: Adding exercise and BT to diet 18 months: Exercise: Adding exercise to diet Behaviour therapy (BT): Adding BT to diet Combined interventions: Adding exercise and BT to diet 24 months: Drug therapy: Adding orlistat to diet + Exercise: Adding exercise to diet and BT Combined interventions: Adding exercise and BT to diet 36 months: Exercise: Adding exercise to diet Behaviour therapy (BT): Adding BT to diet 60 months: Behaviour therapy (BT): Adding BT to diet

-20 -15 -10 -5

Avenell, at al. The British Dietetic Association Ltd 2004. J Hum Nutr Dietet, 17, pp. 293–316

## For Those Who Don't Lose Weight

#### Reassess:

- Understanding and compliance with diet, physical activity, and drug regimen
- Accuracy of weight recordings
- Possible Fluid retention (salt intake, etc)
- Changes in medical condition
- Motivation for change
- Social and personal stress
- Is the provider of health care the root of the problem?


# For Those Who Don't Lose Weight and There is no Cause Except Noncompliance with Diet & Exercise

- Consider changing medication
- consider referral to:
  - Dietitian
  - Behavioral counselor
  - Exercise professional
- Reconsider goal: i.e. simple maintenance or a rest from weight loss efforts
- Discuss surgical options if medically or psychologically indicated


#### **Obesity**

## Surgery


# Estimated Number of Bariatric Operations Performed in the United States, 1992-2003




#### Bariatric surgical techniques for weight loss



LLUSTRATION BY JENNERS FAIRMAN




Sjöström, et al. NEJM. 2004. 351:2683-2693



Sjöström, et al. NEJM. 2004. 351:2683-2693

### Gut to brain signaling



#### **Ghrelin**

- Ghrelin is a recently discovered orexigenic hormone
- Secreted primarily by the stomach and duodenum
- Has been implicated in both mealtime hunger and the long-term regulation of body weight




Figure 1. Mean (±SE) 24-Hour Plasma Ghrelin Profiles in 13 Obese Subjects before and after Diet-Induced Weight Loss.

Breakfast, lunch, and dinner were provided at the times indicated. To convert ghrelin values to picomoles per liter, multiply by 0.296.





Figure 2. Mean (±SE) 24-Hour Plasma Ghrelin Profiles in Subjects Who Underwent Gastric Bypass and in Controls.

The study groups represented are 5 obese subjects who underwent a proximal Roux-en-Y gastric bypass, 10 normal-weight controls, and 5 obese subjects who had recently lost weight by dieting and were matched to the subjects in the gastric-bypass group according to final body-mass index, age, and sex. Breakfast, lunch, and dinner were provided at the times indicated. To convert ghrelin values to picomoles per liter, multiply by 0.296.



(A) Acute effects of intraperitoneally administered [D-Lys-3]-GHRP-6 (200 nmol/mouse) on cumulative food intake in food deprived *ob/ob* obese mice: \*p<0.05, \*\*p<0.01 compared with physiological saline treated controls. (B) Chronic effects of [D-Lys-3]-GHRP-6 administered intraperitoneally (20–200 nmol/mouse every 12 hours for six days) on body weight gain innon-food deprived *ob/ob* obese mice.

Asakawa et al.Gut. 52 (7): 947. (2003)



### شکراً Thank You

المركز الجامعي لأبحاث السمنة كلية الطب حجامعة الملك سعود www.obesitycenter.edu.sa



